XMT-2056

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameXMT-2056
Drug Alias NameXMT-2056
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionStimulator of interferon genes stimulantsAnti-HER2
TargetsStimulator of interferon genesReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMersana Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcMersana Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A